[Skip to the reading](#main) [South Carolina Peptides](/) Common South Carolina myths, tested calmly, charts included. Merchandise absent. [Access](/#access) [Medicine](/#medicine) [Evidence](/#evidence) [Costs](/#costs) [Questions](/#questions) [Access](/#access) [Medicine](/#medicine) [Evidence](/#evidence) [Costs](/#costs) [Questions](/#questions) [Different care paths](/briefing) [Questions for a visit](/question-brief) [Home](/) Evidence # Evidence needs a question it can answer A drug approval, a report of harm and a committee paper do different jobs. Read each for what it shows, then keep its limits attached. [Read this briefing](#reading) Access [Different care paths](/briefing) [Where care happens](/access-briefing) [Prescriber records](/license-briefing) [Clinical roles](/nurse-briefing) [Remote assessment](/telehealth-briefing) [Care across state lines](/state-lines-briefing) Medicine [Pharmacy permits](/pharmacy-briefing) [Compounding conditions](/compounding-briefing) [The HHS draft policy](/draft-policy-briefing) [Weight care](/weight-care-briefing) Evidence [Reading evidence](/evidence-brief) [Discussing risks](/risk-brief) [Research labels](/research-briefing) Costs [The whole cost](/cost-brief) [Coverage decisions](/coverage-brief) Questions [Questions for a visit](/question-brief) [Reporting a concern](/complaint-briefing) Keep the source and its limits together. ## The myth that any official record proves the claim Begin with the exact claim being made. Is it about an approved use, a drug-making issue, planned action over broken rules or the chance of a result? Those are different questions. A link can be official and still be the wrong kind of support for the sentence beside it. Ask what the reader is meant to conclude before asking if the source reaches that finding. FDA is short for the Food and Drug Administration. NDC stands for National Drug Code. This code identifies an entry in a drug directory. FDA says a directory entry or assigned code does not mean approval, in this account of the November 3, 2026 record. [The directory’s own warning](https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory) matters more than the official appearance of the code. Listing and approval are different records. ## Read beyond a headline Close reading keeps the detail in view. Read the linked document far enough to find who published it, what action it sets out and what question it leaves open. A heading is useful for finding the subject. The text below it supplies the limits. Keep a brief note of the claim and the part of the source that answers it. That note is more useful than saving a page without recalling why it mattered. FDA-reviewed labeling belongs to an approved product. Compounded or unapproved drugs do not have equivalent FDA-reviewed details, including pregnancy details, under the September 17, 2026 [compounding distinction](https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers) used here. A page talking about an approved medicine does not show the same evidence for every drug with a related name. ### Reports are signals, not a measured rate FDA’s public adverse-event system collects reports of unwanted experiences associated with drugs. The [reporting system’s limits](https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/fda-adverse-event-monitoring-system-aems-public-dashboard) , checked September 17, 2026, say a report does not show cause or medical confirmation. These reports do not show the rate at which an event happens. Reading a count as a personal chance of harm goes beyond that record. Ask which people the report covers and what comparison, if any, supports the claim being made. If the source cannot answer that question, keep it open. A signal can deserve attention without becoming a rate or a prediction. The next reading takes up concerns about harm and how to ask about them. ### Committee advice has a defined role HHS is short for the Department of Health and Human Services. Committee advice does not itself change the formal compounding ingredient list, as checked November 3, 2026. [FDA’s rulemaking account](https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act) separates advice from a final determination. HHS’s October 30, 2026 draft policy supplies an official account of favorable committee votes for six peptides; it is still not FDA product approval. When a claim relies on a meeting, ask if it sets out the talk, advice or an action taken afterward. Keep those stages in their own words. That avoids making a meeting headline carry more weight than the underlying record. ## Use the record to sharpen the next question Bring the source and a short question to the person treating you. Ask what it supports for the drug and concern being talked about. Ask what remains unknown. There is no need to present a stack of papers or master technical terms to make that exchange useful. A focused question can reveal where the record ends and where a health check has to begin. ## Reading the source ### [FDA drug directory limits](https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory) Read the directory disclaimer before treating a drug code as evidence of approval. ### [FDA report limitations](https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/fda-adverse-event-monitoring-system-aems-public-dashboard) Read the limits on drawing findings from adverse-event reports. ### [HHS policy and appendices](https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf) Read the draft policy itself rather than letting an advisory-vote headline stand in for it. [ Continue with discussing risks ](/risk-brief) South Carolina Peptides [Browse the briefings](/#all-briefings) [Visit questions](/question-brief) [Read the evidence](/evidence-brief) [Text edition](/evidence-brief.md) This guide tests South Carolina peptide myths against the record; it offers no treatment and sells nothing. © South Carolina Peptides